S-5564-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Cory Booker (D-NJ)
What it does
The bill would require the HHS Secretary to set up an Interagency Task Force on Neglected Diseases of Poverty within 180 days. The task force would report on disease prevalence, write treatment guidelines, and advise Congress. The bill would also require CDC grants to states for disease surveillance, grants or cooperative agreements to federally qualified health centers, and education programs for health workers and the public. It would require research on affordable drugs, vaccines, diagnostics, and mosquito control, and it would allow centers of excellence to be funded for up to 5-year periods. It would authorize "such sums as may be necessary" each year starting in fiscal year 2027; actual funding would still require separate appropriations.
Who benefits
People living in poverty, including racial and ethnic minorities and residents of areas with poor water and sanitation, who may gain from better screening and treatment of diseases like Chagas disease and toxoplasmosis. Federally qualified health centers and state health departments that could receive grants. Universities and nonprofit research institutions that could host centers of excellence. Pharmaceutical and biotech developers and clinicians who would get federal research support and clinical guidelines.
Who is hurt
Federal taxpayers, who would bear open-ended authorized spending that is not capped in the bill. Agencies such as HHS, CDC, NIH, EPA, and USDA, which would carry new staffing and coordination duties and may have to shift resources from other priorities. State and local health departments that accept surveillance grants and take on reporting work. Researchers and patients focused on other diseases, who could face competition for limited federal research dollars.
Supporters argue
Supporters argue the bill fills a data and research gap on diseases that one study estimates affect 12 million people in the United States but are poorly tracked. They contend that early screening and treatment are cost-effective, and that applying lessons from the USAID Neglected Tropical Diseases Program, which reports delivering over 3.3 billion treatments, would bring proven methods home. They argue that coordinated surveillance, clinical guidelines, and community health center support would reduce disability and long-term costs.
Opponents argue
Opponents argue the bill authorizes unspecified, open-ended spending with no cap or end date, and prevalence in the United States is admittedly unknown, so the need is not well measured. They contend the new task force, grant programs, and centers of excellence overlap with existing CDC, NIH, and HRSA work, adding bureaucracy. They argue the money may be better directed to established priorities or to existing programs, with oversight through annual appropriations rather than a permanent authorization.
Constitutional context
Congress acts under the Taxing and Spending Clause (Art. I, §8, cl. 1) to fund research and conditional-free grants to states and health centers. Because the grants are voluntary and carry no coercive conditions, the Medicaid-expansion concern in NFIB v. Sebelius (2012) does not appear to apply.
Checks and balances
The executive branch (HHS and partner agencies) gains program and grant-making authority, while Congress keeps control through annual appropriations, required task force recommendations to Congress, and committee oversight.
Historical precedent
Congress has previously authorized disease-specific federal programs, such as the Global Health programs and USAID's Neglected Tropical Diseases Program that the bill cites, but this bill's domestic focus on neglected diseases of poverty appears to be new.